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Background: A previous analysis of 113 National Comprehensive Cancer NetworkVR (NCCNVR ) recommendations reported
that NCCN frequently recommends beyond Food and Drug Administration (FDA)-approved indications (44 off-label
recommendations) and claimed that the evidence for these recommendations was weak.
Methods: In order to determine the strength of the evidence, we carried out an in-depth re-analysis of the 44 off-label
recommendations listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesVR ).
Results: Of the 44 off-label recommendations, 14 were later approved by the FDA and/or are supported by randomized
controlled trial (RCT) data. In addition, 13 recommendations were either very minor extrapolations from the FDA label (n¼ 8) or
were actually on-label (n¼ 5). Of the 17 remaining extrapolations, 8 were for mechanism-based agents applied in rare cancers
or subsets with few available treatment options (median response rate¼ 43%), 7 were based on non-RCT data showing
significant efficacy (>50% response rates), and 2 were later removed from the NCCN Guidelines because newer therapies with
better activity and/or safety became available.
Conclusion: Off-label drug use is a frequent component of care for patients with cancer in the United States. Our findings
indicate that when the NCCN recommends beyond the FDA-approved indications, the strength of the evidence supporting
such recommendations is robust, with a significant subset of these drugs later becoming FDA approved or supported by RCT.
Recommendations without RCT data are often for mechanism-based drugs with high response rates in rare cancers or subsets
without effective therapies.
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Introduction
The National Comprehensive Cancer Network
VR
(NCCN
VR
) is a
not-for-profit alliance of 28 leading cancer centers in the United
States devoted to patient care, research, and education. The
NCCN mission includes improving the quality, effectiveness,
and efficiency of cancer care so that patients can live better lives,
and, in order to do so, NCCN promotes continuous quality
improvement and creates clinical practice guidelines appropriate
for use by patients, clinicians, and other health care decision-
makers. The NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines
VR
) comprised recommendations for the
prevention, diagnosis, and management of malignancies across
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the continuum of care. The guidelines currently apply to over 97%
of patients living with cancer in the United States and incorporate
real-time updates of the rapid advances in cancer research [1].
The NCCN Guidelines are used worldwide, with nearly half
(46.6%) of registered users being from outside the United States
and guideline downloads from over 180 countries [1].
The NCCN Guidelines are developed by panels of experts from
NCCN Member Institutions who diagnose and treat patients
with a broad spectrum of cancers. In addition to common can-
cers, the guidelines deal with complex, aggressive, or rare cancers
(e.g., inflammatory myofibroblastic tumor, hairy cell leukemia,
malignant thymoma, thymic carcinoma), which often reflect an
unmet need for evidence-based therapy approaches. At least year-
ly, clinical cancer experts at the NCCN Member Institutions
identify areas where new data, obtained via multiple modalities
including literature review or external submission requests, have
changed the standard of care, and these areas are discussed at the
annual panel meeting, serving as a basis for possible changes to
the recommendations contained in the guidelines. The NCCN
Guidelines are subject to frequent rounds of review and revision
by disease experts in order to optimize the treatment recommen-
dations. For some guidelines, this results in multiple updates per
year as new data becomes available.
In order to safeguard the objectivity and integrity of the NCCN
Guidelines development and update process, the NCCN has put
in place a comprehensive policy for disclosure of financial rela-
tionships and for management of potential conflicts of interest.
Individuals are disqualified from panel membership if they re-
ceive non-research support from industry of $20,000 or more
from a single entity or more than $50,000 in aggregate from all
entities in a 12-month period. Individual panel members must
recuse themselves from deliberations and/or votes when there
is a meaningful conflict of interest of any level. In addition, the
NCCN does not accept any form of industry or external financial
support for the development of the guidelines. Development of
the NCCN Guidelines is funded exclusively by the Member
Institutions’ dues [1].
In the United States, the Food and Drug Administration
(FDA) is responsible for assuring the safety, efficacy, quality, and
security of human drug and biologic therapies. When the FDA
approves a therapy, it means that the agency has reviewed avail-
able data to determine that the benefits of the therapy outweigh
the risks for the approved indication [2]. Off-label use is the prac-
tice of using an approved drug or biologic for a disease or setting
in which the therapy is not FDA labelled. This practice is com-
mon, particularly for cancer treatment, where off-label use of
therapies is estimated to be around 30% in the United States
[3, 4]. The reasons behind the prevalence of off-label use are
multifaceted, stemming from the relatively narrow indications
often specified on the FDA label, a lack of FDA-approved drugs
available for a certain disease or setting, and the desire to provide
a promising new drug to a patient who might not have access
through an FDA approval or a clinical trial [5]. In addition, even
when there are positive trials supporting the use of an FDA-
approved drug in new settings, the pharmaceutical company may
not pursue FDA approval for these expanded indications due to
the cost of doing so. As a result, off-label drug use is often, but
not always, based on prospective clinical trials, sometimes includ-
ing randomized phase III studies. Insurance coverage of off-label
drug prescriptions is guided through the use of compendia. The
NCCN Drugs & Biologics Compendium (NCCN Compendium)
is widely recognized by public and private insurers alike as an au-
thoritative reference to guide oncology coverage decisions [6].
Our study was conducted in response to the article titled
‘Frequency and Level of Evidence Used in Recommendations by
the National Comprehensive Cancer Network Guidelines
Beyond Approvals of the US Food and Drug Administration:
Retrospective Observational Study’ published in the March 2018
issue of BMJ [7]. Based on an analysis of off-label oncology drug
indications recommended in the NCCN Guidelines, this article
came to the conclusion that ‘The NCCN frequently recommends
beyond the FDA approved indications even for newer, branded
drugs. The strength of the evidence cited by the NCCN support-
ing such recommendations is weak’. Our study sought to deter-
mine the evidence supporting the recommended off-label
indications and the rationale behind these recommendations.
Methods
We determined the versions of the NCCN Guidelines that would have
been available when Wagner et al. downloaded the library of guidelines
on 25 March 2016 and used these versions for our analysis. Working
from the supplementary Table in their paper, which provided the basis
for the results described in the original article [7], we confirmed whether
or not the extrapolation claimed in the original article was accurate,
located the specific setting for the Guideline recommended therapy,
noted any relevant Guideline footnotes that clarified the setting, recorded
the NCCN Category of Evidence and Consensus, and specified the algo-
rithm page containing the extrapolation (see supplementary Table S1,
available at Annals of Oncology online).
Next, we used these versions of the NCCN Guidelines to record what
data were cited as supporting the extrapolation. Most often, these data
were cited either within the algorithm pages (as a footnote or reference)
or within the discussion text. In some cases, generally when the algorithm
had been recently updated and the discussion text was still under devel-
opment, we looked to the Transparency Document. Transparency
Documents are posted on the NCCN website to document all changes
made in response to external requests to the recommendation category
or indication of drugs or biologics, a short summary of the panel discus-
sion, and the rationale for the change. They include references (if applic-
able), and the results of the panel vote for each of the changes listed
(indicated as a subfolder for each guideline entitled ‘Minutes/Evidence’
that can be found in the ‘Transparency: Process and Recommendations’
tab under the NCCN Compendium section).
We furthered our analysis by determining whether the therapy was
subsequently FDA-approved for the Guideline indication and searched
for subsequent published randomized controlled trial (RCT) data in set-
tings where there was no published RCT data supporting the extrapola-
tion at the time of initial analysis.
The above analysis was carried out by two senior NCCN investigators
(RK and ABB) together with an NCCN Oncology Scientist (LAG) and
discussed on several teleconferences in order to carefully examine the
data. We also consulted panel experts in specialties where the NCCN
Guidelines had been questioned in order to validate and crosscheck our
information.
Results
The results of our analysis are shown in Figure 1. As described by
Wagner et al. [7], the 47 drugs that were approved by the FDA be-
tween 1 January 2011 and 31 December 2015 were recommended
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for 113 indications in the NCCN Guidelines. Of these 113 recom-
mended uses, 69 were aligned with the FDA-approved indica-
tions for the therapies. Therefore, the NCCN Guidelines
recommended these therapies in an additional 44 settings beyond
the FDA indications (see Figure 1 and supplementary Table S1,
available at Annals of Oncology online). As indicated in the sup-
plementary Table S1, available at Annals of Oncology online,
100% of these off-label recommendations were supported by
data, which were most often referenced in the NCCN Guidelines
algorithm and/or discussion section (see supplementary Table S1
and Results, available at Annals of Oncology online). Occasionally,
in situations where the therapy had been recently added and the
discussion had not yet been updated, the data were referenced in
the Transparency Document.
To break down these 44 off-label recommendations listed in
the NCCN Guidelines further, our analysis found that 14 of the
indications were either later FDA-approved or were supported by
RCT data [8–12] (see Figure 1 and supplementary Table S1, avail-
able at Annals of Oncology online). Additionally, 13 of the off-
label recommendations were either very minor extrapolations
from the FDA-approved label (n¼ 8, described in more detail in
supplementary Table S1, available at Annals of Oncology online)
or the indications recommended within the NCCN Guidelines
actually represented on-label use (n¼ 5) and were incorrectly
scored by Wagner et al. [7] (supplementary Table S1, available at
Annals of Oncology online).
After subtracting the off-label recommendations that were
later FDA-approved, based on trial data, minor extrapolations
from the label, and/or uses that were actually on-label, a total of
17 off-label NCCN Guidelines recommendations that were based
on lower-level data remained. These 17 indications could be fur-
ther grouped into 3 categories: (i) significant agent activity in
rare cancers or subsets with few treatment options (n¼ 8) (me-
dian response rate ¼ 43%) [13–21]; (ii) non-RCT showing high
(over 50%) response rates (n¼ 7) [22–27]; or (iii) recommenda-
tions that were later removed from the NCCN Guidelines based
on data showing that new therapies had better efficacy and/or
safety (n¼ 2) [28–32].
A detailed discussion of the off-label recommendations listed
in the NCCN Guidelines that were not supported by RCT, and
comments from disease experts on why these therapies are appro-
priate in the given settings, is included in the supplementary
Results, available at Annals of Oncology online.
Discussion
As described by Wagner et al. [7], 47 drugs that were approved by
the FDA (1 January 2011 through 31 December 2015) were rec-
ommended by NCCN Guidelines for 113 indications, 69 of which
were aligned with FDA-approved indications, and 44 of which
were extrapolations (see Figure 1 and supplementary Table S1,
available at Annals of Oncology online). Wagner et al. [7] claimed
that 36% of these recommendations were made with no evidence
given. Yet, our review found that 100% of the off-label recom-
mendations were supported by data, which were most often refer-
enced in the NCCN Guidelines algorithm and/or discussion
section or, more rarely, in the Transparency Document. In add-
ition, 14 of the 44 extrapolations (32%) in the NCCN Guidelines
were later FDA-approved or were supported by RCT data
(Figure 1) and an additional five (11%) were actually consistent
with FDA on-label use (total¼ 19/44 [43%]). Therefore, in many
cases, evidence- and consensus-based treatment recommenda-
tions such as those within the NCCN Guidelines make promising
therapies available to patients months to years before FDA
approval.
The NCCN Guideline algorithms aim to graphically display
treatment pathways, which can often be complex, in as clear and
concise a manner as possible. To accomplish this, important
details about certain treatment options are sometimes listed
within footnotes (e.g. previous therapy requirements for trifluri-
dine/tipiracil for colorectal cancer; panobinostat or pomalido-
mide for multiple myeloma) and the flow of the algorithm
provides important context regarding the treatment options
offered at each setting (e.g. previous therapy requirements for
nivolumab in kidney cancer; specific disease setting for crizotinib
in NSCLC). In several cases, Wagner et al. listed a supposed off-
label extrapolation that actually represented an on-label use once
the context of the algorithm flow and relevant footnotes were
taken into account.
Physicians have the responsibility to ensure that their patients
receive the best possible treatment, and, at the same time, share
the societal responsibility for judicious use of limited resources—
two tasks that can at times appear to be in conflict. Responsible
physicians not only strive to make evidence-based treatment
decisions, when possible, but also consult with the patient, taking
into account their wishes. The value of a therapy for a specific pa-
tient cannot be purely interpreted based on P values, hazard
ratios, and survival outcomes. In addition, cancer treatment is
often applicable to small numbers of patients that, especially for
lethal diseases, cannot afford the time and expense that a large
RCT would entail. Hence, physicians must often make decisions
based on other types of compelling evidence. Cancer patients and
oncologists struggling to wade through the complex, and often
confusing, data emerging from clinical trials need recommenda-
tions that outline evidence-based treatment options across a var-
iety of clinical situations, including those for which there is no
FDA-approved therapy available.
The purpose of the NCCN Guidelines is to provide insight into
treatment strategies for lethal diseases that are often complicated.
Disease experts who serve on the NCCN Panels are charged with
evaluating the disease landscape to define settings where there is
robust evidence to guide treatment and also use their clinical ex-
perience to help fill gaps in evidence, giving patients treatment
options across the disease continuum. As a result, payers look to
NCCN as a responsible party to help guide this complex morass
of disease settings and the complicated array of drugs and drug
combinations.
Importantly, over 20% of the cancer burden in the United
States comprised rare malignancies [33] (and an additional sub-
stantial portion represents rare subsets of common cancers),
where it would take years to accrue an RCT; furthermore, such
trials in these uncommon cancers may be prohibitively expensive.
Hence, data from RCTs are not and may never be available for a
substantial subgroup of patients with cancer. Indeed, few FDA-
approved therapies exist for many patients with rare cancers.
Clinical trial design for rare cancers or subsets of cancer is chang-
ing to attenuate this challenge. FDA approvals are increasingly
based on phase II trials for diseases where phase III trials would
Annals of Oncology Original article
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not be feasible. Furthermore, basket studies which test the efficacy
of a drug that targets a specific mutation across tumor types are
becoming increasingly common. However, while changes to the
FDA approval process for rare cancer treatments are ongoing,
many rare cancers have few or no treatment options that are
FDA-approved or supported by RCT data. Physicians have an ob-
ligation to support therapeutic recommendations for patients
with rare tumors, particularly when the tumor biology and best
47 drugs approved by the FDA between January 1, 2011 and
December 31, 2015 were listed in the NCCN Guidelines for 113
indications as reviewed in Wagner et al7
69 of the NCCN
recommendations for
these drugs aligned with
the FDA indications
Wagner et al7 reported that the NCCN
Guidelines contained an additional 44
recommendations beyond the FDA
indication on March 25, 2016
(113–69 = 44)
See supplemental Table 1
n = 17
Other NCCN
expansions
n = 8
Extrapolation is minor
Supplemental Table 1:
#4, 13, 16, 17, 27, 28,
32, 43
n = 5
Extrapolation does not exist
Supplemental Table 1: #6, 8, 11, 24, 36
(Wagner et al7 missed footnotes,
guideline discussion, or misread)
n = 2
Later removed from the
Guidelines
Supplemental Table 1:
#2, 20
n = 8
Rare diseases or subsets
with few treatment
options
Supplemental Table 1:
#9, 15, 23, 26, 35, 37,
41, 42
n = 7
Non-randomized trial(s) with
high (>50%) response rates
Supplemental Table 1:
#3, 7, 14, 29, 30, 31, 39
n = 13
Extrapolation does
not exist or is minor
n = 14
Supplemental Table 1:
•   9 NCCN expansions later FDA
approved (includes 4 with RCT,
#10, 12, 19, 25; and 5 without
RCT, #21, 22, 33, 38, 40)
•   5 additional expansions not FDA
approved, but supported by RCT
(#1, 5, 18, 34, 44)
Figure 1. Consort diagram of off-label recommendations in the National Comprehensive Cancer Network (NCCN) guidelines. Of the 44 off-
label recommendations, our analysis found that 14 of the indications were later approved by the Food and Drug Administration (FDA) and/
or supported by randomized controlled trial (RCT) data. In addition, 13 of these recommendations were identified to be either very
minor extrapolations from the FDA label (n¼ 8) or were actually on-label as described in the NCCN Guidelines (n¼ 5). Of the 17 remaining
extrapolations, 8 recommendations were for rare cancers or subsets with few available treatment options, 7 recommendations were based
on non-RCT data showing high (>50% response rates), and 2 recommendations were later removed from the NCCN Guidelines based
on data showing that new therapies had better efficacy and/or safety.
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available evidence supports the benefit of therapy. Finally, for
some therapies with remarkable efficacy, an RCT may not meet
the equipoise criteria (meaning that the better arm is uncertain)
that provide the ethical foundation on which these trials are built.
In contrast to the study by Wagner et al., a recent study
reviewed the indications listed in the NCCN Compendium for 43
cancer drugs that were approved between 1999 and 2011 and
compared these with the FDA-approved indications [34]. Of the
253 off-label uses across the 43 drugs reviewed in the study, 91%
were deemed a ‘well-accepted off-label use’ by the authors, mean-
ing the drug received either a Category 1 or Category 2A NCCN
Guidelines recommendation in that setting [1, 34]. Additionally,
65% of the off-label uses were for cancer types not represented in
the FDA labeling at the time of analysis. Off-patent drugs were
found to have more ‘well-accepted off-label uses’ than on-patent
drugs. The authors of this study came to the conclusion that steps
should be taken to better align FDA-labeling with real-world clin-
ical cancer care in cases where high-quality data exist.
Internationally, the same argument could be made, encouraging
regulatory and reimbursement authorities to continually update
indications for use and safety based on the evolution of high qual-
ity data generated after the initial approved labelling—with the
NCCN Guidelines as an example.
There are limitations to our study. Twenty-five of the 113 ana-
lyzed NCCN recommendations have not been FDA approved to
date. Studies have shown that for drugs approved based on
single-arm trials or expedited FDA pathways, unrecognized side-
effects are sometimes later reported [35]. Although NCCN does
not accept any form of industry support for guideline develop-
ment and has strict policies in place restricting support received
by panelists, it remains conceivable that even limited financial or
other undefined incentives might yield conflicts of interest.
In conclusion, our findings are in agreement with previous re-
search [34] that the NCCN recommendations for systemic agents
are based upon scientific evidence in settings frequently beyond
the FDA-approved indications. In most cases, the strength of the
evidence cited by the NCCN supporting such recommendations
is robust. Recommendations without supporting data from RCT
are often for mechanism-based drugs in rare cancers or subsets
with no effective approved therapies. In these cases, the NCCN
recommendations allow for treatment, often with high response
rates, giving these patients a chance for therapeutic benefit that
they would not otherwise have. The NCCN asserts that when ef-
fective drugs are available—often with strong evidence support-
ing their use—patients should have access to these therapies,
even if they do not have an FDA-approved indication for that
specific clinical context.
Funding
None declared.
Disclosure
R. K. receives research funding from Incyte, Genentech, Merck,
Serono, Pfizer, Sequenom, Foundation Medicine, Konica
Minolta, Grifols, and Guardant, as well as consultant fees from X
Biotech, Loxo, NeoMed, and Actuate Therapeutics, speaker fees
from Roche, and is a shareholder in IDbyDNA and in Curematch
Inc. D. S. E. is an advisor for BeyondSpring Pharmaceuticals,
Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly & Co,
Genentech, Golden Biotech Corp, and Guardant Health Inc. S. M.
H. receives fees for scientific advisory boards, consulting, or serv-
ing as an expert witness for ADC Therapeutics, Celgene
Corporation, Corvus, Innate, Kiowa Hakka Kirin, Millennium
Pharmaceuticals Inc, Miragen, Portola, Seattle Genetics, Takeda
Pharmaceuticals North America Inc, and Verastem. S. K. K.
receives research funding for clinical trials to the institution from
Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie,
Medimmune, Novartis, Roche-Genentech, and Amgen as well as
participating in consulting/advisory boards (with no personal
payments) through Celgene, Takeda, Janssen, KITE, Merck,
Abbvie, Medimmune, Genentech, Amgen and (with personal pay-
ment) Oncopeptides, and Adaptive; in addition, he receives hono-
raria from Dr. Reddys Lab and Ono Pharmaceuticals. M. v. M.
receives research funding from Deciphera Pharmaceuticals,
Blueprint Medicines, Lilly, Novartis, and Immune Design; she also
serves as a consultant for Deciphera Pharmaceuticals. A. B. B.
receives research funding from Novartis, Acerta, Celgene,
Advanced Accelerator Applications, Infinity Pharmaceuticals
(data monitoring committee), Merck Sharp and Dohme, Taiho
Pharmaceutical, Bristol-Myers Squibb, Medimmune/
AstraZeneca, Xencor, and Bristol-Myers Squibb (data monitoring
committee), as well as functioning in a consulting or advisory role
for Bristol-Myers Squibb, Guardant Health, Eli Lilly & Company,
Exelixis, Purdue Pharma, Harborside (CME presentations),
Xcenda, NCCN (meeting presentations), Emron (editorial board,
publications), Inventive Health Inc, Axio, Genentech, Bayer,
Merck, Rafael Pharmaceuticals, Astellas (data monitoring com-
mittee member), and Terumo. L. M. has disclosed that she has no
relevant financial relationships. R. W. C. and L. A. G. are employed
by NCCN. R. K., D. S. E., S. M. H., S. K. K., L. M., M. v. M., and A.
B. B. serve on NCCN Panels, Committees, and/or Boards.
References
1. National Comprehensive Cancer Network. 2018; https://www.nccn.org/
(6 August 2019, date last accessed).
2. U.S. Food and Drug Administration. Development & Approval Process
(Drugs). 2018; https://www.fda.gov/Drugs/DevelopmentApprovalProc
ess/default.htm (6 August 2019, date last accessed).
3. Kalis JA, Pence SJ, Mancini RS et al. Prevalence of off-label use of oral
oncolytics at a community cancer center. J Oncol Pract 2015; 11(2):
e139–143.
4. Conti RM, Bernstein AC, Villaflor VM et al. Prevalence of off-label use
and spending in 2010 among patent-protected chemotherapies in a
population-based cohort of medical oncologists. J Clin Oncol 2013;
31(9): 1134–1139.
5. Burstein HJ. Off-label use of oncology drugs: too much, too little, or just
right? J Natl Compr Canc Netw 2013; 11(5): 505–506.
6. The NCCN Drugs & Biologics Compendium (NCCN Compendium
VR
).
2018; https://www.nccn.org/professionals/drug_compendium/default.
aspx (6 August 2019, date last accessed).
7. Wagner J, Marquart J, Ruby J et al. Frequency and level of evidence
used in recommendations by the National Comprehensive Cancer
Network guidelines beyond approvals of the US Food and Drug
Administration: retrospective observational study. BMJ 2018; 360:
k668.
8. Kumar SK, Laplant BR, Reeder CB et al. Randomized phase 2 trial of two
different doses of ixazomib in patients with relapsed multiple myeloma
not refractory to bortezomib. Blood 2015; 126: 3050–3050.
Annals of Oncology Original article
Volume 30 | Issue 10 | 2019 doi:10.1093/annonc/mdz232 | 1651
9. Andtbacka RH, Kaufman HL, Collichio F et al. Talimogene laherparep-
vec improves durable response rate in patients with advanced melanoma.
J Clin Oncol 2015; 33(25): 2780–2788.
10. Flynn JM, Byrd JC, Kipps TJ et al. Obinutuzumab (GA101) 1,000 mg ver-
sus 2,000 mg in patients with chronic lymphocytic leukemia (CLL):
results of the phase II GAGE (GAO4768g) trial. J Clin Oncol 2014;
32(Suppl 15): 7083–7083.
11. Hutson TE, Lesovoy V, Al-Shukri S et al. Axitinib versus sorafenib as
first-line therapy in patients with metastatic renal-cell carcinoma: a rand-
omised open-label phase 3 trial. Lancet Oncol 2013; 14(13): 1287–1294.
12. Leboulleux S, Bastholt L, Krause T et al. Vandetanib in locally advanced
or metastatic differentiated thyroid cancer: a randomised, double-blind,
phase 2 trial. Lancet Oncol 2012; 13(9): 897–905.
13. Dickson MA, Tap WD, Keohan ML et al. Phase II trial of the CDK4 in-
hibitor PD0332991 in patients with advanced CDK4-amplified well-dif-
ferentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31(16):
2024–2028.
14. Shaw AT, Kim DW, Mehra R et al. Ceritinib in ALK-rearranged non-
small-cell lung cancer. N Engl J Med 2014; 370(13): 1189–1197.
15. Subbiah V, Rohren E, Huh WW et al. Phase 1 dose escalation trial of
intravenous radium 223 dichloride alpha-particle therapy in osteosar-
coma. J Clin Oncol 2014; 32(Suppl 15): TPS10600.
16. Drilon A, Wang L, Hasanovic A et al. Response to cabozantinib in
patients with RET fusion-positive lung adenocarcinomas. Cancer Discov
2013; 3(6): 630–635.
17. Drilon AE, Sima CS, Somwar R et al. Phase II study of cabozantinib for
patients with advanced RET-rearranged lung cancers. J Clin Oncol 2015;
33(Suppl 15): Abstract 8007.
18. Butrynski JE, D’Adamo DR, Hornick JL et al. Crizotinib in ALK-
rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;
363(18): 1727–1733.
19. Camidge DR, Ou S-H, Shapiro G et al. Efficacy and safety of crizotinib in
patients with advanced c-MET-amplified non-small cell lung cancer
(NSCLC). J Clin Oncol 2014; 32(Suppl 15): 8001.
20. Tiacci E, Park JH, De Carolis L et al. Targeting mutant BRAF in relapsed
or refractory hairy-cell leukemia. N Engl J Med 2015; 373(18):
1733–1747.
21. Hyman DM, Puzanov I, Subbiah V et al. Vemurafenib in multiple non-
melanoma cancers with BRAF V600 mutations. N Engl J Med 2015;
373(8): 726–736.
22. Kumar SK, Berdeja JG, Niesvizky R et al. Safety and tolerability of ixazo-
mib, an oral proteasome inhibitor, in combination with lenalidomide
and dexamethasone in patients with previously untreated multiple mye-
loma: an open-label phase 1/2 study. Lancet Oncol 2014; 15(13):
1503–1512.
23. Berdeja JG, Hart LL, Mace JR et al. Phase I/II study of the combination
of panobinostat and carfilzomib in patients with relapsed/refractory mul-
tiple myeloma. Haematologica 2015; 100(5): 670–676.
24. Gopal AK, Kahl BS, de Vos S et al. PI3Kdelta inhibition by idelalisib in
patients with relapsed indolent lymphoma. N Engl J Med 2014; 370(11):
1008–1018.
25. Zingone A, Kwok ML, Manasanch EE et al. Phase II clinical and correla-
tive study of carfilzomib, lenalidomide, and dexamethasone followed by
lenalidomide extended dosing (CRD-R) induces high rates of MRD
negativity in newly diagnosed multiple myeloma (MM) patients. Blood
2013; 122: 538.
26. Treon SP, Tripsas CK, Meid K et al. Carfilzomib, rituximab, and dexa-
methasone (CaRD) treatment offers a neuropathy-sparing approach for
treating Waldenstrom’s macroglobulinemia. Blood 2014; 124(4):
503–510.
27. Tetzlaff M, Clos A, Gangar P, Talpur R. Phase II trial of brentuximab
vedotin for CD30þ cutaneous T-cell lymphomas and lymphoprolifera-
tive disorders. Blood. 2013; 122: Abstract 367.
28. Boudreault JS, Touzeau C, Moreau P. Triplet combinations in relapsed/
refractory myeloma: update on recent phase 3 trials. Expert Rev Hematol
2017; 10(3): 207–215.
29. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to
trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006;
354(24): 2619–2621.
30. Li BT, Shen R, Buonocore D et al. Ado-trastuzumab emtansine in
patients with HER2 mutant lung cancers: results from a phase II basket
trial. J Clin Oncol 2017; 35(Suppl): Abstract 8510.
31. Ma H, Su Z, Sun F, Zhao N. The activity and safety of novel proteasome
inhibitors strategies (single, doublet and triplet) for relapsed/refractory
multiple myeloma. Acta Oncol 2018; 57(2): 290–296.
32. Mazieres J, Peters S, Lepage B et al. Lung cancer that harbors an HER2
mutation: epidemiologic characteristics and therapeutic perspectives.
J Clin Oncol 2013; 31: 1997–2003.
33. DeSantis CE, Kramer JL, Jemal A. The burden of rare cancers in the
United States. CA Cancer J Clin 2017; 67(4): 261–272.
34. Shea MB, Stewart M, Van Dyke H et al. Outdated prescription drug
labeling: how FDA-approved prescribing information lags behind real-
world clinical practice. Ther Innov Regul Sci 2018: 52(6): 771–777.
35. Downing NS, Shah ND, Aminawung JA et al. Postmarket safety events
among novel therapeutics approved by the US Food and Drug
Administration between 2001 and 2010. JAMA 2017; 317(18): 1854–1863.
Original article Annals of Oncology
1652 | Kurzrock et al. Volume 30 | Issue 10 | 2019
